KalVista Pharmaceuticals CDO Christopher Yea Exercises Options and Sells Shares

On May 27, 2026, Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, exercised 33,800 employee stock options at an exercise price of $7.07 per share. The options were 100% vested and expired on May 24, 2027. Following the exercise, Yea immediately sold all 33,800 acquired shares at a weighted average price of $26.7818 per share, with the sales occurring in multiple transactions ranging from $26.78 to $26.79 per share. After these transactions, Yea's direct ownership of KalVista common stock decreased from 263,718 shares to 229,918 shares. The Form 4 filing documents these routine insider transactions involving option exercises and subsequent stock sales.